Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I

Pia Recker
University Hospital Cologne

Bodo Bernhard Beck
University Hospital Cologne

Przemyslaw Sikora
Lublin Medical University

Heike Göbel
University Hospital Cologne

Markus Josef Kemper
Asklepios Klinik Hamburg

Angel Nazco
Nuestra Señora de Candelaria University Hospital

Cristina Martin-Higueras
University of La Laguna

Bernd Hoppe (Bernd.Hoppe@knz-bonn.de)
German Hyperoxaluria Center

Article

Keywords: primary hyperoxaluria, calcium-oxalate deposition, liver, fibrosis, systemic oxalosis

Posted Date: April 5th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1488940/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Patients with primary hyperoxaluria type I (PHI) are prone to develop early kidney failure. Systemic deposition of calcium-oxalate (CaOx) crystals starts, when renal function declines and plasma oxalate (Pox) increases. All tissue, but especially bone, heart and eyes are affected. However, liver involvement, as CaOx deposition or chronic hepatitis/fibrosis has never been reported. We examined liver specimen from 19 PHI patients (aged 1.5 to 52 years at sample collection), obtained by diagnostic biopsy (1), at autopsy (1), or transplantation (17). With polarization microscopy, birefringent CaOx crystals located in small arteries, but not within hepatocytes were found in 3/19 patients. Cirrhosis was seen in one, fibrosis in 10/19 patients, with porto-portal and nodular fibrosis (n=1), with limitation to the portal field in 8 and/or to central areas in 5 patients. Unspecific hepatitis features were observed in 7 patients. Fiber proliferations were detectable in 10 cases and in one sample transformed Ito-cells (myofibroblasts) were found. Iron deposition, but also megakaryocytes as sign of extramedullary erythropoiesis were found in 9, or 3 patients, respectively. Overall, liver involvement in patients with PHI was more pronounced, as previously described. However, CaOx deposition was negligible in liver, although the oxalate concentration there must be highest.

Introduction

Currently three types of primary hyperoxaluria (PH I - III) can be accurately defined by substrate analysis in the urine and then confirmed by genetic testing [1-3]. They constitute rare autosomal-recessive inborn errors of hepatic glyoxylate metabolism resulting in extremely increased endogenous oxalate synthesis. Since oxalate cannot be metabolized in mammals it is primarily eliminated via the kidneys. The high urinary oxalate excretion (typically > 0.8-1 mmol/1.73m²/24 hours, normal < 0.5), results in calcium-oxalate (CaOx)-deposition within the renal parenchyma (nephrocalcinosis/oxalosis) and/or recurrent stone formation (urolithiasis), the clinical hallmarks of the primary hyperoxalurias (1-5).

Type I primary hyperoxaluria (PH I, MIM 604285), is caused by deficient or absent activity of liver-specific alanine:glyoxylate aminotransferase (AGT, [6]). It represents the most frequent and most severe type of PH. In a substantial subgroup (about 10 %) of patients, end-stage kidney failure (ESKF) occurs early, e.g. in the first year of life (infantile oxalosis). In the long-run, the vast majority of adults will develop ESKF between the third and fifth decade of life [7,8]. With advanced renal failure the disease turns into a lethal multi-systemic disorder making renal replacement therapy and, so far, subsequent liver-kidney transplantation necessary. Recently, however, a new treatment option, at least for PH I was reported. An RNA interference medication (Oxlumo™, Alnylam Pharmaceuticals, USA) blocks a specific enzyme related to the oxalate production (glycolate oxidase) as substrate reduction therapy. It is available for repeated subcutaneous injection and may prevent the necessity for liver transplantation [9]. Next to that current standard of care treatment with vitamin B6 (VB6) reduces oxalate production in a subgroup of patients and then can even lead to normalization of urinary oxalate excretion [2]. Therefore, also this group of patients would not need liver, but only kidney transplantation, if necessary.

Primary hyperoxaluria type II (PHII, MIM 260000, 604296) occurs as a result of deficient (ubiquitous) glyoxylate reductase/hydroxypruvate reductase (GRHPR) enzyme activity [10]. In general type II shows a milder clinical course, however, recent data showed, that up until 50 % of PH 2 patients are in chronic kidney failure (CKD) and 25 % experience ESKF [11]. PH II accounts for less than 10 % of all PH cases in the PH registries. In case of ESKF isolated kidney transplantation is mainly regarded as sufficient but there are emerging reports, that also liver-kidney transplantations are necessary in problematic cases [12,13].

Primary hyperoxaluria type III is known since 2010 when a third causative gene (HOGA1) coding for hydroxy-oxo-glutarate aldolase type 1 was first described [14,15]. Patients with PH III present with frequently recurring kidney stones even in early childhood, remain stone formers also in adulthood and, in the contrary to previous reports, can eventually develop CKD, but also ESKF [16,17]. However, no transplant procedure has been reported so far in PH III.

In the face of severely compromised renal function in PH, and here especially in PH I, plasma oxalate (Pox) concentration rises and exceeds the supersaturation threshold at levels > 30 μmol/L (normal: < 7.4 μmol/L, [8]) what will invariably result in systemic deposition of calcium-oxalate salts (oxalosis). The devastating effects of oxalosis are causing cardiomyopathy, cardiac conduction disturbances, heart block, vasculopathy, treatment resistant anemia, debilitating oxalate osteopathy and retinopathy (Figure 1). If untreated early death has also been well documented [1,2]. Thus when advanced, the primary hepatic defect which first manifests within the urogenital tract becomes a devastating multi-systemic disorder.

Interestingly, although the liver carries the cause and its transplantation is the only curative treatment option in PH I, there has been no systematic evaluation of liver tissue to document potential other liver affection in PH I, than the enzyme defect. It is well known that prolonged time on hemodialysis (HD) negatively affects outcome and that progressive general vasculopathy in systemic oxalosis is one of the main factors contributing to the moribund condition of advanced disease [18].
We report the first systematic analysis of liver tissue findings in PH I patients suffering from ESKF and systemic oxalosis across all age groups from infantile oxalosis to late onset disease.

**Material And Methods**

Liver tissue samples were taken from 19 patients with PH I, aged 1.5 - 52 years at time of specimen collection, and their status of systemic oxalosis was described. Genetic background was known in all patients (Table 1). Clinical information on age at first symptom, age at diagnosis, age at ESKF, mode and time on dialysis and transplantation procedures as well as current clinical status are shown in Table 1. The study was approved by the local institutional review boards and patients and/or their care takers had signed an informed consent (IRB approvals Cologne 06-231; Bonn 113/14, both Germany, Lublin, Poland KE-0254/118/2016 and Tenerife, Spain CHUC_2020_79). Clinical data were stored in a secured and encrypted online database (www.ph-registry.net). All study related methods were carried out in accordance with relevant guidelines and regulations (Declaration of Helsinki).

Most tissue (n=17) was available after combined or sequential liver-kidney transplantation. In one case each, liver tissue was taken at diagnostic biopsy or at autopsy, the latter providing samples of other organs in addition to the liver (Figure 1). With the exception of the biopsy specimen, we had received multiple large area cuts of approximately 5 cm in diameter from the explanted liver. All pieces available were later histologically examined.

The tissue blocks were fixed in formaldehyde, dehydrated, embedded in paraffin, sectioned at 1-2 µm for routine staining and the following five routine stains were applied: Hematoxylin-eosin (H&E) staining, Van Gieson's, Gomorri, Periodic acid-Schiff (PAS) and Iron stain.

Additionally, some tissue was investigated further using histochemical stains (chlor-acetate-sterase) and immuno-histochemistry methods, e.g. extramedullary hematopoiesis with CD61 (patient 5 and 7), muscle and myofibroblasts with α-actin (patient 3) and bile duct proliferation with CK7 (patient 3).

To look for CaOx depositions within the liver, the hematoxylin-eosin staining of all specimens were examined with a polarization filter for the typical birefringent crystals.

**Results**

All clinical and follow up data of the patients are depicted in Table 1. It is to mention that diagnosis was delayed in 13/19 patients, with a minimum of 1.9 to a maximum of 37 years between first symptom and diagnosis. Patient 11 was only diagnosed with severe systemic oxalosis and in a disastrous condition, although her sister had already died due to PH I after a combined liver-kidney transplantation (LKTx) years before. No family screening had been performed and diagnosis was only established when she had developed advanced systemic oxalosis (Figure 1).

Seven (two children, five adults) of the 19 patients died, two promptly after transplantation (Tx) procedures, two post septicemia 1 and 5 years after transplantation, two patients without obvious transplant-related reason in long-term follow up and one patient (patient 11) meanwhile on maintenance HD, but not transplantable because of severe systemic oxalosis. Combined LKTx as first Tx procedure was performed in 7 patients and it was attempted in one young patient (patient 7), but she died at Tx procedure. Sequential LKTx was performed in 4 patients. One patient lost kidney function due to recurrent CaOx deposition promptly (10 days) after the kidney transplantation (KTx). Three patients needed a second liver grafting, one of them twice.

Only LTx was performed in two patients, who later died after transplantation (patient 1 and 14). In 4 patients KTx was performed before LTx or LKTx, as the correct diagnosis was not available at time of first transplantation. One further VB6 sensitive patient (17) had received an isolated KTx as first Tx procedure. The transplant was lost because of mal-compliance to medications. Six years later she received a sequential liver and then kidney transplantation.

The results of all histological examinations are summarized in Table 2. Calcium-oxalate deposition in the liver as typical birefringent crystals was detected by polarization microscopy in three patients. The crystals were located in small arteries, but not within hepatocytes (Figure 2, 3).

The five routine stains showed different types of fibrosis in the biopsy specimen (Figure 4). Tiny porto-portal fibrosis together with a leucocytic infiltration of the portal fields and the adjoining parenchyma in the sense of an interface-hepatitis was found in patient 5 (Fig. 4 A). In the autopsy case (patient 11) the fibrosis was very advanced towards a cirrhotic remodeling (Fig. 4 B). One sample showed a porto-portal fibrosis together with a nodular fibrosis (patient 10, Fig. 4 C and D), other cases presented with a limitation of the fibrosis to the portal field (patients 1, 2, 4, 6, 8, 9, 12, 18) and/or to central areas (patients 1, 3, 8, 9 and 13). The fibrosis in the sample of patient 10 was much more distinctive.
compared to the others. Unspecified hepatitis features were also seen in seven other samples, which were limited to the portal fields (patients 2, 3, 5, 7, 8, 9 and 10).

Sinus fiber proliferations were detectable in nine cases (patients 2, 3, 5-10 and 18). In one sample transformed Ito-cells (myofibroblasts) were observed by α-actin-stain (patient 3).

In addition there were iron deposits as indicators of either hemolysis or red blood cell transfusions. In one case they were seen in larger quantities in the portal fields (patient 5). In 6 other samples there were only some iron deposits located in the sinus and central areas (patients 1, 6 and 15-17, 19). Two further cases showed tiny portal in addition to high-grade sinuous and central iron depositions (patients 7 and 13).

In three patients it was possible to detect megakaryocytes by the special immune-histological stain CD 61, which confirmed the presence of extramedullary hematopoiesis (patients 2, 5 and 7).

In patient 11, diagnosis and treatment were so delayed that distinctive systemic oxalosis developed with manifestations especially in kidney, skin, liver, bone marrow and myocardium, as is depicted in figure 1 and table 3. The oxalate crystals in the skin caused vascular ischemic necrosis, which became superinfected in the course of the disease. The damage of the myocardium, caused by CaOx deposition, finally led to heart failure and consecutively death.

Discussion

Literature reports on systemic oxalosis in patients with PH I give evidence on CaOx deposits and crystal-induced damage in many organs, such as kidneys, bones, vessels, retina, myocardium and even the central nervous system [1-3, 19-21]. Although the disease causing enzyme defect of PH I is located in the liver, there is no systematic study searching for structural alteration in the liver of patients with PH I. We were able to retrieve five case reports, at which hepatic CaOx deposition was described to take place in the media of the small, but also bigger arteries, as well as in the connective tissue of the portal areas, but not overtly in the liver parenchyma [22-26]. In one patient micronodular cirrhosis was found, which had, however, not affected the patient [24]. Also, crystal deposition in the gall bladder wall was found in another patient [27].

Our findings indicate that there is no uniform histological pattern of liver tissue changes in patients with PH I. All specimen showed different types of liver involvement and it is speculative, on whether or not the changes were truly related to PH I or to other, though unclassified reasons.

In accordance to the case reports mentioned above, we found CaOx deposition in liver arterioles of only three PH I patients [22-26]. So, in general, oxalate deposition in the liver occurs, but we would have expected a much more pronounced accumulation in the organ of oxalate overproduction. It is remarkable that there is a cirrhotic remodeling in 2 of 3 samples which had CaOx crystal deposition. It is, however, discussable on whether or not there is a causal relationship of these phenomena. Maybe the crystals are a secondary incident, which is caused by the fibrosis, for example by constricting the blood flow in parts of the liver. In result of this, CaOx deposits more easily and forms growing crystals. In turn, the crystals may also constrict the blood flow, damage endothelium and cause a necrosis of the surrounding parenchyma and subsequent fibrosis. Both may later result in a vicious circle.

Because of the correlation of CaOx crystal deposition and liver cirrhosis, it maybe interesting to take a special look at the connection between cirrhosis and the course of disease itself. For Patient 11, who had hepatic CaOx crystal deposition, the diagnosis of PH I was made only after ESKF had occurred and 27.7 years after the first symptom had appeared. Therefore, this patient did not get an adequate, disease specific therapy and even maintenance HD was not adapted to the needs of PH I: aggressive, more or less daily HD and even additional nightly intermittent peritoneal dialysis [27-29]. In this patient the course of disease was fatal and the tissue damage in the conducting system of the heart, caused by oxalosis, finally led to death (figure 1). The other patient with CaOx crystal deposition in the liver (patient 10) was treated by isolated kidney transplantation, before the diagnosis of PH I was made. Before that, she was dialyzed for a long time (108 months). As the true diagnosis was unknown, the dialysis regimen was also not adequate for PH I, as only routine (3 times weekly) hemodialysis was performed. The third patient was on aggressive hemodialysis (6 times 3 hours per week) but also for a long period of time (72 months before transplantation). Therefore, the CaOx deposition in liver can be explained either by inadequate dialysis regimens or the long period of dialysis in all cases. It is a known factor also, that the duration of dialysis before transplantation negatively affects the outcome, which, of course, may also lead way to more pronounced oxalate deposition [18].

Nevertheless, we would have had expected much more crystal deposition in the liver in all patients examined. As oxalate is produced in the liver, the oxalate concentration in hepatic tissue and later in the arteries must be high, which should induce parenchymal deposition, like it does in every other body organ. It is well known, that PH I is very heterogenous in its clinical appearances, even within families and with the same genotype [8]. Though, especially in patients with overt systemic oxalosis leading to death, the liver deposits are just minimal. This leaves us speculating, that liver tissue may be protected from crystal attachment or ameliorate the transport of oxalate out of the liver cells promptly into
the blood vessels. Further research is clearly needed here to better understand this phenomenon, which may be helpful to find new treatment possibilities.

Interestingly, fibrotic remodeling of liver was found in every patient, and fiber proliferation, especially in sinus and central vein, were seen in nearly all patients. In addition, in many samples leucocytic infiltration of the portal fields with predominantly lymphocytes were visible. Both, fiber proliferation and inflammatory infiltrates, but especially fibrosis are signs of true liver damage. However, as we only found hepatic CaOx deposition in three patients and as these deposits were not located in the hepatocytes, but only in the vessel walls, it is questionable on whether the underlying disease (=enzyme defect) was the major culprit? Nevertheless, the histological changes do not appear to be age related and hence may not be based on other secondary factors.

Overall, to conclude our findings, crystal deposition in the liver of PH I patient only rarely takes place and is restricted to arteries and portal tissue. Nevertheless, liver involvement defined as fibrotic remodeling was more pronounced as previously described. This was, however, clearly not related to the amount of crystal deposition in the liver.

Declarations

Acknowledgments/Funding

This project has received funding in part from the European Union's Horizon 2020 research and innovation program under the ERA-NET Cofund action N° 643578° to BBB (DFG grant BE 6072/1-1). It has also received funds from the German Research Foundation (DFG; Grant within the SFB/TRR 57 to BH). CMH is funded by a Juan de la Cierva postdoctoral grant from the Spanish Ministry of Science (Reference FJC2018-036199-I).

Statement of authors contribution

Pia Recker: collected clinical data of all patients, organized and interpreted data and wrote the paper
Bodo Bernhard Beck: was concepting the paper, supervised data collection, interpreted data, wrote and reviewed paper
Przemyslaw Sikora: collected the polish part of clinical and histological data, reviewed the paper
Heike Göbel: performed histological analysis and interpretation, reviewed the paper
Markus Josef Kemper: collected clinical information of his patients included, reviewed the paper
Angel Nazco: performed the spanish part of the histological analysis, reviewed the paper
Cristina Martin-Higueras: provided the clinical data of the spanish patients included, wrote and reviewed paper
Bernd Hoppe: concept of paper, data collection, supervision, wrote paper, reviewed paper

Competing interests

CMH is a consultant of Dicerna a NovoNordisk company, USA/Denmark. BBB received consulting fees from Alnylam. BH is also an employee of Dicerna a NovoNordisk company, USA/Denmark. The other authors have nothing to declare.

Data availability statement

The patients data are placed in the mentioned registry (IRB votes for that registry available). The histology slides are available on request to corresponding author.

References

1. Cochot P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013 Aug 15;369(7):649-58. doi: 10.1056/NEJMrA1301564. Erratum in: N Engl J Med. 2013 Nov 28;369(22):2168. PMID: 23944302.
2. Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012 Jun 12;8(8):467-75. doi: 10.1038/nrneh.2012.113. PMID: 22688746.
3. Lorenzo V, Torres A, Salido E. Primary hyperoxaluria.Nefrologia. 2014 May 21;34(3):398-412. English, Spanish. doi: 10.3265/Nefrologia.pre2014.Jan.12335.Epub 2014 Apr 30. PMID: 24798559.
4. Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Nephrol 2001;12:1986-1993
5. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int 2009; 75:1264-1271
6. Danpure C, Jennings P. Peroxisomal alanine glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS 1986;201:20-4.
7. Zhao F, Bergstrahl EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS; Investigators of Rare Kidney Stone Consortium. Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Clin J Am Soc Nephrol. 2016 Jan 7;11(1):119-26. doi: 10.2215/CJN.02810315. Epub 2015 Dec 10. PMID: 26656319; PMCID: PMC4702224.
8. Mandrisi G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, Rumsby G; OxalEurope Consortium. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014 Dec;86(6):1197-204. doi: 10.1038/ki.2014.222. Epub 2014 Jul 2. PMID: 24988064.
9. Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van’t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Melambo KA, Lu J, Sweetser MT, Garg PP, Vaishnav AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr 13;384(13):1216-1226. doi: 10.1056/NEJMoA201712. PMID: 33789010.
10. Cramer S, Ferree P, Lin K, Milliner D, Holmes R. The gene encoding hydroxyproline reductase is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet 1999;8:2063-9
11. Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB, Oosterveld MJ, Suttle AM, Neuhaus T, Adams B, Cochat P, Salido E, Lipkin GW, Hoppe B, Hulton SA; OxalEurope Consortium. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 2019 Dec;96(6):1389-1399. doi: 10.1016/j.kint.2019.08.018. Epub 2019 Sep 3. PMID: 31685312.
12. Del Bello A, Cointault O, Delas A, Kamar N. Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation. Am J Transplant. 2020 Jun;20(6):1752-1753. doi: 10.1111/ajt.15829. Epub 2020 Mar 19. PMID: 32090455.
13. Dhondup T, Lorenz EC, Milliner DS, Lieske JC. Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report. Am J Transplant. 2018 Jan;18(1):253-257. doi: 10.1111/ajt.14418. Epub 2017 Aug 14. PMID: 28681512; PMCID: PMC5739996.
14. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monaco CG, Feinsstein S, Ben-Shalom E, Magen D, Weissman I, Cahron C, Frishberg Y. Am J Hum Gen 2011;88:193-200.
15. Monaco CG, Rossetti S, Belostosky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg J, Milliner DS. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 2011;6:2289-2295
16. Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bachetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int. 2021 Apr 16;S0085-2538(21)00386-0. doi: 10.1016/j.kint.2021.03.031. Epub ahead of print. PMID: 33865885.
17. Singh P, Granberg CF, Harris PC, Lieske JC, Licht JH, Weiss A, Milliner DS. Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report. Am J Kidney Dis. 2022 Jan;79(1):125-128. doi: 10.1053/j.ajkd.2021.05.016. Epub 2021 Jul 7. PMID: 34245816; PMCID: PMC8692335.
18. Jamieson NV, Group EPTS. A 20-year experience of combined liver-kidney transplantation for primary hyperoxaluria (PH1): the European transplant registry experience 1084-2004. Am J Nephrol 2005;25:282-9.
19. Herrmann G, Krieg T, Weber M et al. Unusual painful sclerotic like plaques on the legs of a patient with late diagnosis of primary hyperoxaluria type I. Br J Dermatol 2004;151:1104-1107.
20. Sriman K, Kekre NS, Gopalakrishnan G. Primary hyperoxaluria and systemic oxalosis. Indian J Urol 2007; 23: 79-80.
21. Marangella M, Vitale C, Petraruolo M et al. Bone content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int 1995; 48: 182-187.
22. Kogiso T, Tokushige K, Hashimoto E, Miyakata C, Taniai M, Torii N, Omori A, Kotera Y, Egawa H, Yamamoto M, Nagata M, Shiratori K. Primary hyperoxaluria complicated with liver cirrhosis: A case report. Hepatol Res. 2015 Dec;45(12):1251-5. doi: 10.1111/hepr.12494. Epub 2015 Mar 3. PMID: 25594663.
23. Kazama-Saegusa S, Kazama JJ, Sugaya H, Takamiya H, Terano A, Ichiyama A. A case of late onset primary hyperoxaluria type I (PH-I) presented with black liver. Clin Nephrol. 1998 Sep;50(3):184-7. PMID: 9776423.
24. Tanniover B, Mejia A, Foster SV, Mubarak A. Primary hyperoxaluria involving the liver and hepatic artery: images of an aggressive disease. Kidney Int. 2010 Apr;77(7):651. doi: 10.1038/ki.2009.350. PMID: 20224594.
25. Patra S, Vij M, Varghese JS, Rela M. Aggressive primary hyperoxaluria involving the liver in an adult. Liver Int. 2012 Nov;32(10):1564. doi: 10.1111/j.1478-3231.2012.02845.x. Epub 2012 Jul 12. PMID: 22784009.
26. Dimashkieh H, Koehler A. Primary hyperoxaluria affecting the liver. Arch Pathol Lab Med. 2002 Oct;126(10):1250-1. doi: 10.5858/2002-126-1250-PHATL. PMID: 12385336.

27. Hoppe B, Kemper M, Bokenkamp A, Portale A, Cohn R, Langman C. Plasma calcium-oxalate supersaturation in children with primary hyperoxaluria and endstage renal failure. Kidney Int 1999;56:268-74.

28. Hoppe B, Graf D, Offner G, et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol 1996;10:488-492.

29. Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 2006;70:1642-1648.

Tables

**Table 1:** clinical data of all patients examined. iKTx = isolated kidney transplantation, LTx = liver transplantation, LKTx = combined liver/kidney transplantation, SLKTx = sequential liver-kidney transplantation, all transplantation cadaveric unless otherwise stated; PD = peritoneal dialysis, HD = hemodialysis, ALF = acute liver failure, eGFR = estimated glomerular filtration rate (CKD-EPI formula), SOF = stable organ function, *immediate kidney graft failure and need for ongoing hemodialysis treatment.
| Patient No. | Family No. | Sex | AGXT Genotype                  | 1st Symptom (years) | Diagnosis (years) | ESFR (years) | Dialysis time (months) and mode | PLP prior ESRF | Transplantation type and year | Outcome                  |
|------------|------------|-----|--------------------------------|---------------------|------------------|---------------|---------------------------------|----------------|-------------------------------|--------------------------|
| 1          | F1         | m   | c.409G>T; c.508G>A             | 0.1                 | 0.2              | 0.2           | 15 PD/HD                        | no             | LTx related 2007               | death 2.3 years          |
| 2          | F2         | f   | c.1079G>A; homozygous          | 0.1                 | 0.4              | 0.2           | 17 PD/HD                        | no             | LTx and re LTx in 06/2011     | SOF, eGFR 95 ml/min      |
| 3          | F3         | m   | c.331C>T; c.454T>A            | 0.5                 | 0.5              | 0.5           | 12 PD/HD                        | no             | LTx related 08/2008, 2nd KTx in 2021 | HD from 01/20-03/21; now SOF, eGFR 77 ml/min |
| 4          | F4         | m   | c.508G>A; c.33dupC            | 0.3                 | 0.3              | 0.3           | 15 PD/HD                        | no             | LTx 2007                      | SOF, eGFR 26.3 ml/min    |
| 5          | F5         | m   | c.533G>A homozygous           | 2.5                 | 5.8              | 2.5           | 62 PD/HD                        | no             | iKTx 05/2001, LTx 09/2003     | SOF, no further follow up available |
| 6          | F6         | m   | del6_8 homozygous             | 1.1                 | 8.3              | 6.8           | 28 HD                           | no             | iKTx 04/2008, LTx 05/2009     | Lost KTx at age 18 years, since on HD |
| 7          | F7         | f   | c.508G>A homozygous           | 2                   | 4.7              | 5.4           | 72 PD/HD                        | no             | attempted LTx 05/2009         | death at 11.4 years      |
| 8          | F6         | f   | del6_8 homozygous             | 11.6                | 13.5             | 14.5          | 6 HD                            | yes            | LTx 07/2008                   | SOF, eGFR 92 ml/min at age 29 years |
| 9          | F8         | m   | c.508G>A homozygous           | 2                   | 17               | 14            | 156 HD                          | no             | iKTx 2000*, LTx 2003*, LTx 2006* and prompt iKTx after Tx failure | death 22 years post last Tx |
| 10         | F9         | f   | c.33delC homozygous           | 5                   | 13               | 10            | 108 HD                          | no             | iKTx 1996, LTx 2002           | Died suddenly at age 22 with SOF, eGFR 47 ml/min |
| 11         | F10        | f   | c.508G>A homozygous           | 0.3                 | 28               | 28            | 42 HD                           | no             | none                          | death 31.6 years         |
| 12         | F11        | f   | c.508G>A homozygous           | 6                   | 43               | 40.5          | 20 HD                           | no             | LTx 2006                      | Death in 2011 due to septicemia |
| 13         | F12        | f   | c.508G>A; c.1084G>A          | 42                  | 48,1             | 47.9          | 15 HD                           | no             | LTx 1/2009                    | SOF, eGFR 40 ml/min      |
| 14         | F13        | m   | c.449T>C; c.1110_1111delCG     | 0.1                 | 36               | 47            | 17 HD                           | no             | LTx in 2017                   | death at 49 years, septicemia |
| 15         | F14        | m   | c.733_734del AA              | 0.7                 | 12               | 20            | 51 HD                           | no             | LTX in 2018                   | back on                  |
Table 2: Results of histological examinations, (+) low specification, + modest specification, ++ high specification, CaOx = calcium-oxalate

| Patient N° | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 |
|------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|
| Porto-portal fibrosis | + |    |    |    |    |    |    |    |    |    | ++ |    |    |    |    |    |    |    |    |
| Nodular fibrosis |    |    |    |    |    |    |    |    |    |    |    | + |    |    |    |    |    |    |    |
| Portal fibrosis | + | (+) | (+) | + | + | + | (+) | (+) |    |    |    |    |    |    |    |    |    |    |    |
| Central fibrosis | (+) | ++ | + | + | + | + | (+) | (+) |    |    |    |    |    |    |    |    |    |    |    |
| Cirrhosis |    |    |    |    |    |    |    |    |    |    |    |    | + |    |    |    |    |    |    |    |
| Unspecific hepatitis (predominantly portal) | + | + | + | + | (+) | + | ++ |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Sinusoidal fiber proliferation | (+) | (+) | + | + | + | + | + | + | (+) | (+) |    |    |    |    |    |    |    |    |    |    |
| Myofibroblasts |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Portal iron deposits | ++ | + |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Sinusoidal and central iron deposits | + | + | (+) | ++ | ++ | + | + | + | + |    |    |    |    |    |    |    |    |    |    |    |
| Extramedullary hematopoiesis | + |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Unspecific cholangitis |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Signs of portal hypertension |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| CaOx crystals |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    | (+) |

Table 3: Presence of oxalate crystals in different organs of the autopsy case (patient 11), NAD = (no appreciable disease), ++ = high, + = modest, (+) = low
Organ | Histology | Oxalate crystals
---|---|---
Kidney | Progressive glomerulonecrosis, tubule atrophy, interstitial fibrosis | ++
Skin (leg) | Superinfected gangrene with attendant venous thrombosis, vasal lumen occluded by crystals | ++
Liver | Cirrhosis | +
Bone marrow | Local fibrosis, resorbing reaction with foam cells | +
Myocardium | Interstitial fibrosis, hypertrophy of cardiomyocytes | +
Lung | Relapsing pulmonary embolism in small arteries without pulmonary infarction | (+)
Spleen | N. A. D. | (+)
Pancreas | N. A. D. | (+)
Lymph node | N. A. D. | (+)
Artery, elastic type | N. A. D. | (+)
Thyroid gland | N. A. D. | (+)

Figures

![Figure 1](image)

Figure 1

Severe systemic oxalosis in patient 11 (autopsy). (A) The oxalate crystals in the skin caused vascular ischemic necrosis, which became superinfected in the course of the disease. (B) The damage of the myocardium, caused by CaOx deposition, finally led to heart failure and consecutively death. (C / D) Birefringent CaOx deposits in the bone marrow and in the kidney. CaOx = calcium-oxalate.
Figure 2
Calcium-oxalate deposition in the liver as typical birefringent crystals detected by polarization microscopy in two patients (A) patient 10, (B) patient 11. The crystals were located in small arteries, but not within hepatocytes.

Figure 3
(A) Small deposits are visible in the center of the image (patient 17), which are apparently fragmented crystalloid structures with pale grayish color within a portal field (the part above in the picture is still columnar epithelium of a bile duct also included); (HE, 40x). (B) The crystalloid structures appear optically polarized birefringent. (Polarization, HE 40x)

Figure 4
The routine stains showed different types of fibrosis in the biopsy specimen: (A) Tiny porto-portal fibrosis together with a lymphocytic infiltration of the portal fields and the adjoining parenchyma in the sense of an interface-hepatitis (patient 5). (B) In the autopsy case (patient 11) fibrosis was very advanced towards a cirrhotic remodeling. (C, D) Porto-portal fibrosis together with a nodular fibrosis (patient 10).